evaluate the pharmaceutical company wegovy on glp 1 Novo Nordisk launches subscription for GLP-1 obesity drugs A big win for Wegovy:

I was too

A retrospective analysis of 105,000+ patients revealed: 40% lower OSA risk with tirzepatide (Zepbound) or semaglutide (Wegovy) vs non-AOM users Lower OSA incidence: 3.12% vs 12.56% Comparable impact between tirzepatide and semaglutide, with tirzepatide showing a slight edge after 6 months This study highlights the potential for AOMs to address obesity and OSA, supporting broader healthcare value through comorbidity reduction

Some 50% of Americans will ...

Even the most affordable option, Byetta, becomes costlier than surgery after around 1.5 years

This affordability equation is expected to shift significantly after the patent on Semaglutide expires in China and India in 2026